Familial Hypercholesterolaemia: from Epidemiology to Genetics – a paradigm shift?
Clinical Certainties and Uncertainties: what remains unresolved?
We are delighted that Professor Andrew Neil, Emeritus Professor of Clinical Epidemiology University of Oxford, Wolfson College will speak at the HEART UK conference on 7 July.
Dr Neil is Emeritus Professor of Clinical Epidemiology at the University of Oxford. He was an Honorary Consultant Physician at the Oxford Centre for Diabetes, Endocrinology & Metabolism (OCDEM) at the Churchill Hospital and, on retirement, was appointed Senior Tutor at Wolfson College, Oxford, for three years before being elected Emeritus Fellow.
He read history at the University of Cambridge and, after graduation, studied Medicine at St Thomas’ Hospital, London. His research has focused on the determinants of coronary heart disease and its prevention, particularly in relation to diabetes, dyslipidaemias and nutrition. He has conducted an extensive programme of clinical research consisting both of large-scale epidemiological studies and randomised controlled trials and published nearly 250 research papers. Outcomes of trials such as the Collaborative Atorvastatin Diabetes Study (CARDS) and epidemiological studies, including the Simon Broome Register of Familial Hyperlipidaemia, have had important implications for evidence-based practice and the organisation and delivery of care. He directed the Simon Broome Register for over twenty years; was a member of the NICE Familial Hypercholesterolaemia (CG71) Guideline Development Panel; was a Senior Research Fellow of the National Institute for Health Research; and is a past Chairman of HEART UK.
This event is intended for healthcare professionals from the UK and receives sponsorship from pharmaceutical companies
- NICE launches review of methods and processes for health technology evaluation
- The Essential Cholesterol Programme for Primary Care
- Add on to take back control. Do we have the solutions to the gaps in our lipid treatment pathway?
- The role of Lp(a) and oxPLs in atherosclerosis
- Lp(a) measurement bias
- Polygenic hypercholesterolaemia: why do we want to know?
- HEART UK Offers Guidance On The Safe Use Of Lipid Lowering Therapy During COVID-19 Pandemic
- Ketogenic Diet and Lipids
- Low Carbohydrate diets, Weight management, Type 2 diabetes and Dyslipidaemia
- Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia